glp 1 in europe GLP-1 Receptor Agonist Market Growth Analysis GLP-1 Receptor Agonist Market Size

doi: 10.1016/S0140-6736(08)61246-5

Mima, A

Novo Nordisks oral Wegovy, approved in December 2025, was the first oral GLP-1 to hit the obesity market

Hormonal changes during the menopause transition can affect appetite, body composition, fat distribution, and energy balance, making weight loss feel more challenging than it once did

What's Next: Orforglipron (oral GLP-1) completing Phase 3 trials with submissions expected by year-end 2025 CEO Dave Ricks expects FDA approval by March 2026 International launches accelerating in China, Brazil, India, and Mexico The GLP-1 market is projected to exceed $100B+ by the early 2030s, and Lilly is positioned as the category leader

In July 2025 , the company announced its making a $2 billion investment to expand manufacturing in RTP and in October 2025 , it pledged $250,000 to Durham Technical Community College to mark their 30th anniversary in the area